Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 6/20 | 0.40 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.35 |
| ▸ | PTGDR | Q13258 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16616292 | 0.89 | SLC6A3 (0.40) | SSTR5ALDH1A1IDO1SCN9A | |
| SCHEMBL16616321 | 0.81 | SSTR5 (0.40) | SSTR5PTGDR2PTGDRIDO1 | |
| SCHEMBL16616530 | 0.81 | SSTR5 (0.35) | SSTR5DHODHIDO1KCNH2FFAR4 | |
| SCHEMBL17535715 | 0.77 | SSTR5 (0.44) | SSTR5ALDH1A1 | |
| SCHEMBL18022477 | 0.76 | SSTR5 (0.47) | SSTR5PTGDR2PTGDRALDH1A1FFAR4 | |
| SCHEMBL16670174 | 0.76 | ALPL (0.36) | SSTR5IDO1KCNH2SCN9A | |
| SCHEMBL17535705 | 0.74 | SSTR5 (0.46) | SSTR5KCNH2 | |
| SCHEMBL17535817 | 0.74 | SLC6A3 (0.44) | SSTR5ALDH1A1 | |
| SCHEMBL16616131 | 0.71 | ALOX5AP (0.33) | DHODHPTGDR2PTGDRALDH1A1IDO1 | |
| SCHEMBL17535933 | 0.71 | SSTR5 (0.42) | SSTR5ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-9353108-B2 | Tetrahydronaphthyridine somatostatin receptor 5 antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-05-31 | — | — | US | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099777-A1 | HETEROCYCLIC COMPOUND | SSTR5, SSTR4, SSTR2 | SSTR5 1/4885DHODH 3605/4885PTGDR2 419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.